Bam

Quote






Getting physicians to convert patients from Humara to one of your other drugs isn't hard. Flooding the airwaves with your tacky commercials shouldn't be confused with creativity or innovation. Nails aren't used for the construction of a rocket. Have fun with your hammer.
 


















anonymous said:
I am shocked the stock has not recovered … is this thing starting to unravel?
Click to expand...
Right now there is a big reordering of the top dogs in pharma based on market cap. Onco and immunology no longer the darlings, cardiometabolic and neuro are the new stars - just look at Lilly and Novo.

Lilly took 15 years to get on another rocket after its big patent cliff - and they had a clear innovation strategy, not just buy stuff and market the hell out of it. Most of the buy-and-market plays they tried were failures. Their COO and CFO also understood innovation well, could effectively message the strategy to the street on their own without a script. I was there at the time, and looking back what's interesting was the big exodus of marketing people to this shiny "new" company in the Chicago suburbs, especially the "you can market anything" types. One of them is now pictured on our website.

So, I wouldn't say we are unraveling, but we are probably in for an extended period of mediocrity. This will not be the decade of endless possibilities we proclaim to the street, it will take a while.
 






Honestly everyone needs to sell this stock right now. Abbvie is so fucked. We have absolutely no pipeline and have been mismanaged for decades.

Skyrizi and vraylar will do alright for a while but as that happens we will gradually transition into a lower tier pharma company. Maybe 20 years from now we find another blockbuster but who knows?

head for the door, sell your stock, and go join another innovative company that’s doing REAL work for patients
 






anonymous said:
Honestly everyone needs to sell this stock right now. Abbvie is so fucked. We have absolutely no pipeline and have been mismanaged for decades.

Skyrizi and vraylar will do alright for a while but as that happens we will gradually transition into a lower tier pharma company. Maybe 20 years from now we find another blockbuster but who knows?

head for the door, sell your stock, and go join another innovative company that’s doing REAL work for patients
Click to expand...
Outsider here. Turn on the TV for 30 minutes and you will see how Abbvie thinks of itself - just flood the zone and wait for it to rain. More ads than even Liberty Mutual. And the Skyrizi song has become almost as annoying. Sure, lots of pharma companies do TV ads, but nothing like this. You all must be embarrassed.
 
























anonymous said:
Honestly everyone needs to sell this stock right now. Abbvie is so fucked. We have absolutely no pipeline and have been mismanaged for decades.

Skyrizi and vraylar will do alright for a while but as that happens we will gradually transition into a lower tier pharma company. Maybe 20 years from now we find another blockbuster but who knows?

head for the door, sell your stock, and go join another innovative company that’s doing REAL work for patients
Click to expand...

The fact that Abbott/Abbvie always spent half on R&D compared
To peers should and does say it all.

This stock isn’t doing anything this decade. Abbott knew this was the end and future and didn’t want it.
 












This company is horrible. Such bullsh$&! Migraine sucks and there is no coverage. The new indication meeting was horrible and this new indication is a damn joke. Cannot wait to get out!
 


















Over the last 4 years, I have met some hardworking Mexicans that barely get paid enough to live yet work long days. While I haven't met this CEO, he doesn't appear to be ethical or hardworking yet he gets paid enough for at least 40 hard-working individuals. I'd wager heavily that the CEO of abbvie would expire from an LD50 dosage of hydrogen cyanide. Hopefully, his bride gets a front-row seat for the show.
 












anonymous said:
I wonder what the floor on the stock price is.

Also wonder how bad it has to get before a big layoff occurs.
Click to expand...
Look at history, what happened to other companies that went over patent cliffs without a good pipeline and a real strategy. Lilly is a good example. It took them a looooong time to recognize doubling down on the same thing wouldn’t work anymore. And during that time there was a mass migration of marketing people from Indianapolis to Chicago, enticed by big money to do what they knew. It made us who we are today.
 






anonymous said:
Look at history, what happened to other companies that went over patent cliffs without a good pipeline and a real strategy. Lilly is a good example. It took them a looooong time to recognize doubling down on the same thing wouldn’t work anymore. And during that time there was a mass migration of marketing people from Indianapolis to Chicago, enticed by big money to do what they knew. It made us who we are today.
Click to expand...
This is spot on. A leading indicator of the issue at AbbVie is the mass exodus of experienced drug developers over the last year in R&D. Those people looked at the pipeline, looked at their colleagues and looked at the organizations will/capability to change and assessed it was time to go.
Now that doesn't mean AbbVie can't still come out of this. They have a formidable war chest to pay for marketing and acquisitions. So BD and Commercial folks could wait to see if big deals and big products to work on emerge in the near future.
 






anonymous said:
I wonder what the floor on the stock price is.

Also wonder how bad it has to get before a big layoff occurs.
Click to expand...
abbvie is known for 3 things:

1. marketing that rivals a consumer products company, just turn on the tv
2. borderline anticompetitive practices that never quite cross the line, but stifle innovation regardless. think patent thickets, very broad non-competes (often enforced), stonewalling competitor clinical trials, etc. it is a very long list
3. dividends

the house of cards created by 1 and 2 is coming down. hard to innovate when you are known for marketing and stifling innovation. but because of 3 i would buy abbv if it goes below 75-ish, because the board will protect dividends at all cost. not good news if you work here, though
 






Top Bottom
Back
Quote